Skip to main content
SpringerLink
Log in

Radiation Therapy

  • Chapter
  • First Online:
Esophageal Squamous Cell Carcinoma

  • 1104 Accesses

Abstract

Radiotherapy is indicated for the treatment of esophageal cancer both with curative intent and with palliative intent. Concurrent chemoradiotherapy is the standard treatment for patients in good condition who can receive chemotherapy, based on the result of randomized trial that compared chemoradiotherapy with radiotherapy alone. For locally advanced unresectable esophageal cancer, definitive chemoradiotherapy is the standard therapy with potentially curative intent. And for resectable esophageal cancer, definitive chemoradiotherapy is a treatment option in an attempt to preserve the esophagus from favorable results of clinical trials. These results are supported by salvage treatment in cases of residual or recurrent disease after chemoradiotherapy. However high mortality rate of salvage surgery and high incidence of late toxicities after chemoradiotherapy with higher radiation dose are important problems to be solved. Neoadjuvant chemoradiotherapy is standard treatment for locally advanced esophageal cancer in Western countries; however it is investigational in Japan. Combination chemotherapy of new agents and new radiotherapy technique such as intensity-modulated radiation therapy, proton-beam therapy, and heavy-particle radiotherapy have been evaluated in clinical trials to improve the treatment results including efficacy and toxicity.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Herskovic A, Martz K, al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V, Cooper J, Byhardt R, Davis L, Emami B (1992) Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 326:1593–1598

    Article  PubMed  CAS  Google Scholar 

  2. al-Sarraf M, Martz K, Herskovic A, Leichman L, Brindle JS, Vaitkevicius VK, Cooper J, Byhardt R, Davis L, Emami B (1997) Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study. J Clin Oncol 15:277–284

    PubMed  CAS  Google Scholar 

  3. Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA Jr, Al-Sarraf M, Byhardt R, Russell AH, Beitler JJ, Spencer S, Asbell SO, Graham MV, Leichman LL (1999) Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85–01). Radiation Therapy Oncology Group. JAMA 281:1623–1627

    Article  PubMed  CAS  Google Scholar 

  4. Kato H, Sato A, Fukuda H, Kagami Y, Udagawa H, Togo A, Ando N, Tanaka O, Shinoda M, Yamana H, Ishikura S (2009) A phase II trial of chemoradiotherapy for stage I esophageal squamous cell carcinoma: Japan Clinical Oncology Group Study (JCOG9708). Jpn J Clin Oncol 39:638–643

    Article  PubMed  Google Scholar 

  5. Kato K, Muro K, Minashi K, Ohtsu A, Ishikura S, Boku N, Takiuchi H, Komatsu Y, Miyata Y, Fukuda H, Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group (JCOG) (2011) Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906). Int J Radiat Oncol Biol Phys 81:684–690

    Article  PubMed  CAS  Google Scholar 

  6. Ohtsu A, Boku N, Muro K, Chin K, Muto M, Yoshida S, Satake M, Ishikura S, Ogino T, Miyata Y, Seki S, Kaneko K, Nakamura A (1999) Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol 17:2915–2921

    PubMed  CAS  Google Scholar 

  7. Ishida K, Ando N, Yamamoto S, Ide H, Shinoda M (2004) Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516). Jpn J Clin Oncol 34:615–619

    Article  PubMed  Google Scholar 

  8. Nishimura Y, Suzuki M, Nakamatsu K, Kanamori S, Yagyu Y, Shigeoka H (2002) Prospective trial of concurrent chemoradiotherapy with protracted infusion of 5-fluorouracil and cisplatin for T4 esophageal cancer with or without fistula. Int J Radiat Oncol Biol Phys 53:134–139

    Article  PubMed  CAS  Google Scholar 

  9. Leong T, Everitt C, Yuen K, Condron S, Hui A, Ngan SY, Pitman A, Lau EW, MacManus M, Binns D, Ackerly T, Hicks RJ (2006) A prospective study to evaluate the impact of FDG-PET on CT-based radiotherapy treatment planning for Oesophageal cancer. Radiother Oncol 78:254–261

    Article  PubMed  Google Scholar 

  10. Mizowaki T, Nishimura Y, Shimada Y, Nakano Y, Imamura M, Konishi J, Hiraoka M (2007) Optimal size criteria of malignant lymph nodes in the treatment planning of radiotherapy for esophageal cancer: evaluation by computed tomography and magnetic resonance imaging. Int J Radiat Oncol Biol Phys 36:1091–1098

    Article  Google Scholar 

  11. Gao XS, Qiao X, Wu F, Cao L, Meng X, Dong Z, Wang X, Gao G, Wu TT, Komaki R, Chang JY (2007) Pathological analysis of clinical target volume margin for radiotherapy in patients with esophageal and gastroesophageal junction carcinoma. Int J Radiat Oncol Biol Phys 67:389–396

    Article  PubMed  Google Scholar 

  12. Akiyama H, Tsurumaru M, Kawamura T, Ono Y (1981) Principles of surgical treatment for carcinoma of the esophagus: analysis of lymph node involvement. Ann Surg 194:438–446

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  13. Tachimori Y, Nagai Y, Kanamori N, Hokamura N, Igaki H (2011) Pattern of lymph node metastases of esophageal squamous cell carcinoma based on the anatomical lymphatic drainage system. Dis Esophagus 24:33–38

    Article  PubMed  CAS  Google Scholar 

  14. Huang W, Li B, Gong H, Yu J, Sun H, Zhou T, Zhang Z, Liu X (2010) Pattern of lymph node metastases and its implication in radiotherapeutic clinical target volume in patients with thoracic esophageal squamous cell carcinoma: a report of 1077 cases. Radiother Oncol 95:229–233

    Article  PubMed  Google Scholar 

  15. Onozawa M, Nihei K, Ishikura S, Minashi K, Yano T, Muto M, Ohtsu A, Ogino T (2009) Elective nodal irradiation (ENI) in definitive chemoradiotherapy (CRT) for squamous cell carcinoma of the thoracic esophagus. Radiother Oncol 92:266–269

    Article  PubMed  CAS  Google Scholar 

  16. Yaremko BP, Guerrero TM, McAleer MF, Bucci MK, Noyola-Martinez J, Nguyen LT, Balter PA, Guerra R, Komaki R, Liao Z (2008) Determination of respiratory motion for distal esophagus cancer using four-dimensional computed tomography. Int J Radiat Oncol Biol Phys 70:145–153

    Article  PubMed  Google Scholar 

  17. Fenkell L, Kaminsky I, Breen S, Huang S, Van Prooijen M, Ringash J (2008) Dosimetric comparison of IMRT vs. 3D conformal radiotherapy in the treatment of cancer of the cervical esophagus. Radiother Oncol 89:287–291

    Article  PubMed  Google Scholar 

  18. Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, Okawara G, Rosenthal SA, Kelsen DP (2002) INT 0123 (Radiation Therapy Oncology Group 94–05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 20:1167–1174

    Article  PubMed  CAS  Google Scholar 

  19. Kenjo M, Uno T, Murakami Y, Nagata Y, Oguchi M, Saito S, Numasaki H, Teshima T, Mitsumori M (2009) Radiation therapy for esophageal cancer in Japan: results of the patterns of care study 1999–2001. Int J Radiat Oncol Biol Phys 75:357–363

    Article  PubMed  Google Scholar 

  20. Lee HK, Vaporciyan AA, Cox JD, Tucker SL, Putnam JB Jr, Ajani JA, Liao Z, Swisher SG, Roth JA, Smythe WR, Walsh GL, Mohan R, Liu HH, Mooring D, Komaki R (2003) Postoperative pulmonary complications after preoperative chemoradiation for esophageal carcinoma: correlation with pulmonary dose-volume histogram parameters. Int J Radiat Oncol Biol Phys 57:1317–1322

    Article  PubMed  Google Scholar 

  21. Wang SL, Liao Z, Vaporciyan AA, Tucker SL, Liu H, Wei X, Swisher S, Ajani JA, Cox JD, Komaki R (2006) Investigation of clinical and dosimetric factors associated with postoperative pulmonary complications in esophageal cancer patients treated with concurrent chemoradiotherapy followed by surgery. Int J Radiat Oncol Biol Phys 64:692–699

    Article  PubMed  Google Scholar 

  22. Asakura H, Hashimoto T, Zenda S, Harada H, Hirakawa K, Mizumoto M, Furutani K, Hironaka S, Fuji H, Murayama S, Boku N, Nishimura T (2010) Analysis of dose-volume histogram parameters for radiation pneumonitis after definitive concurrent chemoradiotherapy for esophageal cancer. Radiother Oncol 95:240–244

    Article  PubMed  Google Scholar 

  23. Konski A, Li T, Christensen M, Cheng JD, Yu JQ, Crawford K, Haluszka O, Tokar J, Scott W, Meropol NJ, Cohen SJ, Maurer A, Freedman GM (2012) Symptomatic cardiac toxicity is predicted by dosimetric and patient factors rather than changes in 18F-FDG PET determination of myocardial activity after chemoradiotherapy for esophageal cancer. Radiother Oncol 104:72–77

    Article  PubMed  PubMed Central  Google Scholar 

  24. Fukada J, Shigematsu N, Takeuchi H, Ohashi T, Saikawa Y, Takaishi H, Hanada T, Shiraishi Y, Kitagawa Y, Fukuda K (2013) Symptomatic pericardial effusion after chemoradiation therapy in esophageal cancer patients. Int J Radiat Oncol Biol Phys 87:487–493

    Article  PubMed  Google Scholar 

  25. Wei X, Liu HH, Tucker SL, Wang S, Mohan R, Cox JD, Komaki R, Liao Z (2008) Risk factors for pericardial effusion in inoperable esophageal cancer patients treated with definitive chemoradiation therapy. Int J Radiat Oncol Biol Phys 70:707–714

    Article  PubMed  Google Scholar 

  26. Shirai K, Tamaki Y, Kitamoto Y, Murata K, Satoh Y, Higuchi K, Nonaka T, Ishikawa H, Katoh H, Takahashi T, Nakano T (2011) Dose-volume histogram parameters and clinical factors associated with pleural effusion after chemoradiotherapy in esophageal cancer patients. Int J Radiat Oncol Biol Phys 80:1002–1007

    Article  PubMed  Google Scholar 

  27. Marks LB, Yorke ED, Jackson A, Ten Haken RK, Constine LS, Eisbruch A, Bentzen SM, Nam J, Deasy JO (2010) Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys 76(3 Suppl):S10–S19

    Article  PubMed  PubMed Central  Google Scholar 

  28. Yorozu A, Dokiya T, Oki Y, Suzuki T (1999) Curative radiotherapy with high-dose-rate brachytherapy boost for localized esophageal carcinoma: dose-effect relationship of brachytherapy with the balloon type applicator system. Radiother Oncol 51:133–139

    Article  PubMed  CAS  Google Scholar 

  29. Akagi Y, Hirokawa Y, Kagemoto M, Matsuura K, Ito A, Fujita K, Kenjo M, Kiriu H, Ito K (1999) Optimum fractionation for high-dose-rate endoesophageal brachytherapy following external irradiation of early stage esophageal cancer. Int J Radiat Oncol Biol Phys 43:525–530

    Article  PubMed  CAS  Google Scholar 

  30. Nishimura Y, Okuno Y, Ono K, Mitsumori M, Nagata Y, Hiraoka M (1999) External beam radiation therapy with or without high-dose-rate intraluminal brachytherapy for patients with superficial esophageal carcinoma. Cancer 86:220–228

    Article  PubMed  CAS  Google Scholar 

  31. Okawa T, Dokiya T, Nishio M, Hishikawa Y, Morita K, Japanese Society of Therapeutic Radiology and Oncology (JASTRO) Study Group (1999) Multi-institutional randomized trial of external radiotherapy with and without intraluminal brachytherapy for esophageal cancer in Japan. Int J Radiat Oncol Biol Phys 45:623–628

    Article  PubMed  CAS  Google Scholar 

  32. Nemoto K, Yamada S, Nishio M, Aoki M, Nakamura R, Matsumoto Y, Sasamoto R, Saitoh Y, Takayama M, Mitsuhashi N, Gomi K, Kanesaka N, Kobayashi M, Ohnishi H, Sasaki S, Tamamura H, Mitsumori M, Nishimura Y, Tsujino K, Takemoto M, Uchida N, Yamamoto M, Shioyama Y, Hirakawa K, Ono S, JASTRO Study Group (2006) Results of radiation therapy for superficial esophageal cancer using the standard radiotherapy method recommended by the Japanese Society of Therapeutic Radiology and Oncology (JASTRO) Study Group. Anticancer Res 26(2B):1507–1512

    PubMed  Google Scholar 

  33. Yamada K, Murakami M, Okamoto Y, Okuno Y, Nakajima T, Kusumi F, Takakuwa H, Matsusue S (2006) Treatment results of chemoradiotherapy for clinical stage I (T1N0M0) esophageal carcinoma. Int J Radiat Oncol Biol Phys 64:1106–1111

    Article  PubMed  Google Scholar 

  34. Ishikawa H, Nonaka T, Sakurai H, Tamaki Y, Kitamoto Y, Ebara T, Shioya M, Noda SE, Shirai K, Suzuki Y, Takahashi T, Nakano T (2010) Usefulness of intraluminal brachytherapy combined with external beam radiation therapy for submucosal esophageal cancer: long-term follow-up results. Int J Radiat Oncol Biol Phys 76:452–459

    Article  PubMed  Google Scholar 

  35. Homs MY, Steyerberg EW, Eijkenboom WM, Tilanus HW, Stalpers LJ, Bartelsman JF, van Lanschot JJ, Wijrdeman HK, Mulder CJ, Reinders JG, Boot H, Aleman BM, Kuipers EJ, Siersema PD (2004) Single-dose brachytherapy versus metal stent placement for the palliation of dysphagia from oesophageal cancer: multicentre randomised trial. Lancet 364:1497–1504

    Article  PubMed  Google Scholar 

  36. Bergquist H, Wenger U, Johnsson E, Nyman J, Ejnell H, Hammerlid E, Lundell L, Ruth M (2005) Stent insertion or endoluminal brachytherapy as palliation of patients with advanced cancer of the esophagus and gastroesophageal junction. Results of a randomized, controlled clinical trial. Dis Esophagus 18:131–139

    Article  PubMed  CAS  Google Scholar 

  37. Gaspar LE, Nag S, Herskovic A, Mantravadi R, Speiser B (1997) American Brachytherapy Society (ABS) consensus guidelines for brachytherapy of esophageal cancer. Clinical Research Committee, American Brachytherapy Society, Philadelphia, PA. Int J Radiat Oncol Biol Phys 38:127–132

    Article  PubMed  CAS  Google Scholar 

  38. Earlam R, Cunha-Melo JR (1980) Oesophageal squamous cell carcinoma: I. A critical review of surgery. Br J Surg 67:381–390

    Article  PubMed  CAS  Google Scholar 

  39. Hancock SL, Glatstein E (1984) Radiation therapy of esophageal cancer. Semin Oncol 11:144–158

    PubMed  CAS  Google Scholar 

  40. Okawa T, Kita M, Tanaka M, Ikeda M (1989) Results of radiotherapy for inoperable locally advanced esophageal cancer. Int J Radiat Oncol Biol Phys 17:49–54

    Article  PubMed  CAS  Google Scholar 

  41. Kawashima M, Kagami Y, Toita T, Uno T, Sugiyama M, Tamura Y, Hirota S, Fuwa N, Hashimoto M, Yoshida H, Shikama N, Kataoka M, Akuta K, Sasaki K, Tamamoto T, Nemoto K, Ito H, Kato H, Yamada S, Ikeda H (2006) Prospective trial of radiotherapy for patients 80 years of age or older with squamous cell carcinoma of the thoracic esophagus. Int J Radiat Oncol Biol Phys 64:1112–1121

    Article  PubMed  Google Scholar 

  42. Shinoda M, Ando N, Kato H et al (2010) A multicenter randomized phase II (rPII)/III study comparing concurrent chemoradiotherapy (CRT) with low-dose cisplatin plus continuous infusion of 5-fluorouracil (LDPF) and standard-dose PF (SDPF) for locally advanced unresectable squamous cell carcinoma of the thoracic esophagus (JCOG0303). J Clin Oncol 28:15s (suppl; abstr 4053)

    Google Scholar 

  43. Nishimura Y, Mitsumori M, Hiraoka M, Koike R, Nakamatsu K, Kawamura M, Negoro Y, Fujiwara K, Sakurai H, Mitsuhashi N (2009) A randomized phase II study of cisplatin/5-FU concurrent chemoradiotherapy for esophageal cancer: short-term infusion versus protracted infusion chemotherapy (KROSG0101/JROSG021). Radiother Oncol 92:260–265

    Article  PubMed  CAS  Google Scholar 

  44. Nishimura Y, Hiraoka M, Koike R, Nakamatsu K, Itasaka S, Kawamura M, Negoro Y, Araki N, Ishikawa H, Fujii T, Mitsuhashi N (2012) Long-term follow-up of a randomized Phase II study of cisplatin/5-FU concurrent chemoradiotherapy for esophageal cancer (KROSG0101/JROSG021). Jpn J Clin Oncol 42:807–812

    Article  PubMed  Google Scholar 

  45. Stahl M, Stuschke M, Lehmann N, Meyer HJ, Walz MK, Seeber S, Klump B, Budach W, Teichmann R, Schmitt M, Schmitt G, Franke C, Wilke H (2005) Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 23:2310–2317

    Article  PubMed  Google Scholar 

  46. Conroy T, Galais MP, Raoul JL, Bouché O, Gourgou-Bourgade S, Douillard JY, Etienne PL, Boige V, Martel-Lafay I, Michel P, Llacer-Moscardo C, François E, Créhange G, Abdelghani MB, Juzyna B, Bedenne L, Adenis A, Fédération Francophone de Cancérologie Digestive and UNICANCER-GI Group (2014) Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. Lancet Oncol 15:305–314

    Article  PubMed  CAS  Google Scholar 

  47. Crosby T, Hurt CN, Falk S, Gollins S, Mukherjee S, Staffurth J, Ray R, Bashir N, Bridgewater JA, Geh JI, Cunningham D, Blazeby J, Roy R, Maughan T, Griffiths G (2013) Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial. Lancet Oncol 14:627–637

    Article  PubMed  CAS  Google Scholar 

  48. Ilson DH, Moughan J, Suntharalingam M et al (2014) RTOG 0436: A phase III trial evaluating the addition of cetuximab to paclitaxel, cisplatin, and radiation for patients with esophageal cancer treated without surgery. J Clin Oncol 32:5s, suppl; abstr 4007

    Article  Google Scholar 

  49. Higuchi K, Komori S, Tanabe S, Katada C, Azuma M, Ishiyama H, Sasaki T, Ishido K, Katada N, Hayakawa K, Koizumi W, Kitasato Digestive Disease and Oncology Group (2014) Definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) in advanced esophageal cancer: a phase 2 trial (KDOG 0501-P2). Int J Radiat Oncol Biol Phys 89:872–879

    Article  PubMed  CAS  Google Scholar 

  50. Bedenne L, Michel P, Bouché O, Milan C, Mariette C, Conroy T, Pezet D, Roullet B, Seitz JF, Herr JP, Paillot B, Arveux P, Bonnetain F, Binquet C (2007) Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 25:1160–1168

    Article  PubMed  CAS  Google Scholar 

  51. Kato K, Nakajima TE, Ito Y, Katada C, Ishiyama H, Tokunaga SY, Tanaka M, Hironaka S, Hashimoto T, Ura T, Kodaira T, Yoshimura K (2013) Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma. Jpn J Clin Oncol 43:608–615

    Article  PubMed  Google Scholar 

  52. Tahara M, Fuse N, Mizusawa J, et al. (2014) Phase I/II trial of chemoradiotherapy concurrent with S-1 and cisplatin in patients with clinical stage II/III esophageal carcinoma: results of the Japan clinical oncology group study JCOG 0604. J Clin Oncol 32, suppl 3; abstr 134

    Google Scholar 

  53. Yano T, Muto M, Hattori S, Minashi K, Onozawa M, Nihei K, Ishikura S, Ohtsu A, Yoshida S (2008) Long-term results of salvage endoscopic mucosal resection in patients with local failure after definitive chemoradiotherapy for esophageal squamous cell carcinoma. Endoscopy 40:717–721

    Article  PubMed  CAS  Google Scholar 

  54. Makazu M, Kato K, Takisawa H, Yoshinaga S, Oda I, Saito Y, Mayahara H, Ito Y, Itami J, Hamaguchi T, Yamada Y, Shimada Y (2014) Feasibility of endoscopic mucosal resection as salvage treatment for patients with local failure after definitive chemoradiotherapy for stage IB, II, and III esophageal squamous cell cancer. Dis Esophagus 27:42–49

    Article  PubMed  CAS  Google Scholar 

  55. Tachimori Y, Kanamori N, Uemura N, Hokamura N, Igaki H, Kato H (2009) Salvage esophagectomy after high-dose chemoradiotherapy for esophageal squamous cell carcinoma. J Thorac Cardiovasc Surg 137:49–54

    Article  PubMed  Google Scholar 

  56. Swisher SG, Wynn P, Putnam JB, Mosheim MB, Correa AM, Komaki RR, Ajani JA, Smythe WR, Vaporciyan AA, Roth JA, Walsh GL (2002) Salvage esophagectomy for recurrent tumors after definitive chemotherapy and radiotherapy. J Thorac Cardiovasc Surg 123:175–183

    Article  PubMed  Google Scholar 

  57. Bosset JF, Gignoux M, Triboulet JP, Tiret E, Mantion G, Elias D, Lozach P, Ollier JC, Pavy JJ, Mercier M, Sahmoud T (1997) Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 337:161–167

    Article  PubMed  CAS  Google Scholar 

  58. Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A, Strawderman M (2001) Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 19:305–313

    PubMed  CAS  Google Scholar 

  59. Lee JL, Park SI, Kim SB, Jung HY, Lee GH, Kim JH, Song HY, Cho KJ, Kim WK, Lee JS, Kim SH, Min YI (2004) A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma. Ann Oncol 15:947–954

    Article  PubMed  CAS  Google Scholar 

  60. Burmeister BH, Smithers BM, Gebski V, Fitzgerald L, Simes RJ, Devitt P, Ackland S, Gotley DC, Joseph D, Millar J, North J, Walpole ET, Denham JW, Trans-Tasman Radiation Oncology Group, Australasian Gastro-Intestinal Trials Group (2005) Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol 6:659–668

    Article  PubMed  Google Scholar 

  61. Tepper J, Krasna MJ, Niedzwiecki D, Hollis D, Reed CE, Goldberg R, Kiel K, Willett C, Sugarbaker D, Mayer R (2008) Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 26:1086–1092

    Article  PubMed  CAS  Google Scholar 

  62. van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, Cuesta MA, Blaisse RJ, Busch OR, ten Kate FJ, Creemers GJ, Punt CJ, Plukker JT, Verheul HM, Spillenaar Bilgen EJ, van Dekken H, van der Sangen MJ, Rozema T, Biermann K, Beukema JC, Piet AH, van Rij CM, Reinders JG, Tilanus HW, van der Gaast A, CROSS Group (2012) Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366:2074–2084

    Article  PubMed  Google Scholar 

  63. Kato K, Hashimoto J, Ito Y, et al. (2014). Phase II study of neoadjuvant chemoradiotherapy with cisplatin plus 5-fluorouracil and elective nodal irradiation for stage II/III esophageal squamous cell carcinoma: a 2-year follow up. J Clin Oncol 32, suppl 3; abstr 129

    Google Scholar 

  64. Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J, Australasian Gastro-Intestinal Trials Group (2007) Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 8:226–234

    Article  PubMed  CAS  Google Scholar 

  65. Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A, Gebski V, Australasian Gastro-Intestinal Trials Group (2011) Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 12:681–692

    Article  PubMed  Google Scholar 

  66. Nakamura K, Kato K, Igaki H, Ito Y, Mizusawa J, Ando N, Udagawa H, Tsubosa Y, Daiko H, Hironaka S, Fukuda H, Kitagawa Y, Japan Esophageal Oncology Group/Japan Clinical Oncology Group (2013) Three-arm phase III trial comparing cisplatin plus 5-FU (CF) versus docetaxel, cisplatin plus 5-FU (DCF) versus radiotherapy with CF (CF-RT) as preoperative therapy for locally advanced esophageal cancer (JCOG1109, NExT study). Jpn J Clin Oncol 43:752–755

    Article  PubMed  Google Scholar 

  67. Rosenberg JC, Franklin R, Steiger Z (1981) Squamous cell carcinoma of the thoracic esophagus: an interdisciplinary approach. Curr Probl Cancer 5:1–52

    Article  PubMed  CAS  Google Scholar 

  68. Coia LR, Soffen EM, Schultheiss TE, Martin EE, Hanks GE (1993) Swallowing function in patients with esophageal cancer treated with concurrent radiation and chemotherapy. Cancer 71:281–286

    Article  PubMed  CAS  Google Scholar 

  69. Ikeda E, Kojima T, Kaneko K, Minashi K, Onozawa M, Nihei K, Fuse N, Yano T, Yoshino T, Tahara M, Doi T, Ohtsu A (2011) Efficacy of concurrent chemoradiotherapy as a palliative treatment in stage IVB esophageal cancer patients with dysphagia. Jpn J Clin Oncol 41:964–972

    Article  PubMed  Google Scholar 

  70. Nemoto K, Takai Y, Ogawa Y, Kakuto Y, Ariga H, Matsushita H, Wada H, Yamada S (1998) Fatal hemorrhage in irradiated esophageal cancer patients. Acta Oncol 37:259–262

    Article  PubMed  CAS  Google Scholar 

  71. Ishikura S, Nihei K, Ohtsu A, Boku N, Hironaka S, Mera K, Muto M, Ogino T, Yoshida S (2003) Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus. J Clin Oncol 21:2697–2702

    Article  PubMed  CAS  Google Scholar 

  72. Morota M, Gomi K, Kozuka T, Chin K, Matsuura M, Oguchi M, Ito H, Yamashita T (2009) Late toxicity after definitive concurrent chemoradiotherapy for thoracic esophageal carcinoma. Int J Radiat Oncol Biol Phys 75:122–128

    Article  PubMed  Google Scholar 

  73. Gaspar LE, Winter K, Kocha WI, Coia LR, Herskovic A, Graham M (2000) A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207): final report. Cancer 88:988–995

    Article  PubMed  CAS  Google Scholar 

  74. Kumar S, Dimri K, Khurana R, Rastogi N, Das KJ, Lal P (2007) A randomised trial of radiotherapy compared with cisplatin chemo-radiotherapy in patients with unresectable squamous cell cancer of the esophagus. Radiother Oncol 83:139–147

    Article  PubMed  CAS  Google Scholar 

  75. Brunner TB, Rupp A, Melzner W, Grabenbauer GG, Sauer R (2008) Esophageal cancer. A prospective phase II study of concomitant-boost external-beam chemoradiation with a top-up endoluminal boost. Strahlenther Onkol 184:15–22

    Article  PubMed  Google Scholar 

  76. Nishimura Y, Nagata K, Katano S, Hirota S, Nakamura K, Higuchi F, Soejima T, Sai H, Japanese Society for Esophageal Diseases (2003) Severe complications in advanced esophageal cancer treated with radiotherapy after intubation of esophageal stents: a questionnaire survey of the Japanese Society for Esophageal Diseases. Int J Radiat Oncol Biol Phys 56:1327–1332

    Article  PubMed  Google Scholar 

  77. Sugahara S, Tokuuye K, Okumura T, Nakahara A, Saida Y, Kagei K, Ohara K, Hata M, Igaki H, Akine Y (2005) Clinical results of proton beam therapy for cancer of the esophagus. Int J Radiat Oncol Biol Phys 61:76–84

    Article  PubMed  Google Scholar 

  78. Mizumoto M, Sugahara S, Nakayama H, Hashii H, Nakahara A, Terashima H, Okumura T, Tsuboi K, Tokuuye K, Sakurai H (2010) Clinical results of proton-beam therapy for locoregionally advanced esophageal cancer. Strahlenther Onkol 186:482

    Article  PubMed  Google Scholar 

  79. Lin SH, Komaki R, Liao Z, Wei C, Myles B, Guo X, Palmer M, Mohan R, Swisher SG, Hofstetter WL, Ajani JA, Cox JD (2012) Proton beam therapy and concurrent chemotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys 83:e345–e351

    Article  PubMed  PubMed Central  Google Scholar 

  80. Akutsu Y, Yasuda S, Nagata M, Izumi Y, Okazumi S, Shimada H, Nakatani Y, Tsujii H, Kamada T, Yamada S, Matsubara H (2012) A phase I/II clinical trial of preoperative short-course carbon-ion radiotherapy for patients with squamous cell carcinoma of the esophagus. J Surg Oncol 105:750–755

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo, Japan

    Yoshinori Ito

Authors
  1. Yoshinori Ito
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yoshinori Ito .

Editor information

Editors and Affiliations

  1. Department of Surgery, International Goodwill Hospital, Yokohama, Kanagawa, Japan

    Nobutoshi Ando

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer Japan

About this chapter

Cite this chapter

Ito, Y. (2015). Radiation Therapy. In: Ando, N. (eds) Esophageal Squamous Cell Carcinoma. Springer, Tokyo. https://doi.org/10.1007/978-4-431-54977-2_13

Download citation

  • DOI: https://doi.org/10.1007/978-4-431-54977-2_13

  • Published:

  • Publisher Name: Springer, Tokyo

  • Print ISBN: 978-4-431-54976-5

  • Online ISBN: 978-4-431-54977-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation